华海药业：子公司HB0056注射液项目新增适应症获临床试验批准

Core Viewpoint - Huahai Pharmaceutical's subsidiary Shanghai Huao Tai Biopharmaceutical Co., Ltd. and Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd. have received approval from the National Medical Products Administration for a new indication for the HB0056 injection project, specifically for atopic dermatitis [1] Group 1 - The HB0056 injection is intended for the treatment of atopic dermatitis and is in the form of an injection [1] - The clinical trial application for the new indication has been accepted and approved by the National Medical Products Administration [1] - The company has invested approximately RMB 91.69 million in the HB0056 project to date [1]